Thursday, October 15, 2026

Coffee Futures Is 3% Up In The Last 10 Sessions

Coffee Futures Is 3% Up In The Last 10 Sessions

(VIANEWS) - Coffee (KC) has been up by 3.74% for the last 10 sessions. At 08:54 EST on Monday, 31 July, Coffee (KC) is $160.95.

Volume

Today's last reported volume for Coffee is 3089, 84.58% below its average volume of 20042.28.

Volatility

Coffee's last week, last month's, and last quarter's current intraday variation average was a negative 0.30%, a negative 0.52%, and a positive 2.02%, respectively.

Coffee's highest amplitude of average volatility was 1.04% (last week), 1.53% (last month), and 2.02% (last quarter), respectively.

Commodity Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Coffee's commodity is considered to be overbought (>=80).

News about

  • According to DailyForex on Monday, 31 July, "The ability of the USD/MXN to create and sustain lower price realms has been significant and the higher price of Crude Oil which is being demonstrated now, adds to this flourish of strength for the Mexican Peso."
  • According to DailyForex on Sunday, 30 July, "The West Texas Intermediate Crude Oil market rallied a bit during the trading week, breaking toward the $80 level. "
  • According to FXStreet on Monday, 31 July, "That said, the US Dollar Index (DXY) remains indecisive around 101.75 following the previous day's retreat while prices of Gold and Crude Oil eased to around $1,957 and $80.20 of late."

More news about Coffee (KC).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com